Literature DB >> 7284378

Catabolism of thymidine in human blood platelets: purification and properties of thymidine phosphorylase.

C Desgranges, G Razaka, M Rabaud, H Bricaud.   

Abstract

A pyrimidine nucleoside phosphorylase was partially purified from human blood platelets. The purified enzyme, as well as crude enzyme preparations, catalyses the phosphorolysis of thymidine and deoxyuridine, but not of uridine, and is able to catalyse direct pentosyl transfer from these deoxyribonucleosides to uracil or thymine; this enzyme has the properties of a thymidine phosphorylase. It has a molecular weight of about 110,000 and is composed of two identical subunits; it is phosphate dependent, has a maximal activity at a pH value of 5.7, and an isoelectric point of 4.4. This enzyme was mainly of cytoplasmic origin. Although platelet thymidine phosphorylase could promote the degradation or synthesis of thymidine, intact platelets degraded thymidine but were not able to synthesize thymidine from thymine. Blood platelets may play an important role in the degradation of plasma thymidine.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7284378     DOI: 10.1016/0005-2787(81)90174-x

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  18 in total

1.  Human platelet-derived endothelial cell growth factor is homologous to Escherichia coli thymidine phosphorylase.

Authors:  G J Barton; C P Ponting; G Spraggon; C Finnis; D Sleep
Journal:  Protein Sci       Date:  1992-05       Impact factor: 6.725

Review 2.  Structural analyses reveal two distinct families of nucleoside phosphorylases.

Authors:  Matthew J Pugmire; Steven E Ealick
Journal:  Biochem J       Date:  2002-01-01       Impact factor: 3.857

3.  Hematopoietic gene therapy restores thymidine phosphorylase activity in a cell culture and a murine model of MNGIE.

Authors:  J Torres-Torronteras; A Gómez; H Eixarch; L Palenzuela; G Pizzorno; M Hirano; A L Andreu; J Barquinero; R Martí
Journal:  Gene Ther       Date:  2011-03-31       Impact factor: 5.250

4.  Regeneration of the antiviral drug (E)-5-(2-bromovinyl)-2'-deoxyuridine in vivo.

Authors:  C Desgranges; G Razaka; F Drouillet; H Bricaud; P Herdewijn; E De Clercq
Journal:  Nucleic Acids Res       Date:  1984-02-24       Impact factor: 16.971

5.  Enzymatic characterization of AMP phosphorylase and ribose-1,5-bisphosphate isomerase functioning in an archaeal AMP metabolic pathway.

Authors:  Riku Aono; Takaaki Sato; Ayumu Yano; Shosuke Yoshida; Yuichi Nishitani; Kunio Miki; Tadayuki Imanaka; Haruyuki Atomi
Journal:  J Bacteriol       Date:  2012-10-12       Impact factor: 3.490

Review 6.  Thymidine phosphorylase, 2-deoxy-D-ribose and angiogenesis.

Authors:  N S Brown; R Bicknell
Journal:  Biochem J       Date:  1998-08-15       Impact factor: 3.857

7.  Metabolic breakdown of [3H]thymidine and the inability to measure human lymphocyte proliferation by incorporation of radioactivity.

Authors:  J Bodycote; S Wolff
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

8.  Deoxynucleoside stress exacerbates the phenotype of a mouse model of mitochondrial neurogastrointestinal encephalopathy.

Authors:  Beatriz Garcia-Diaz; Caterina Garone; Emanuele Barca; Hamed Mojahed; Purification Gutierrez; Giuseppe Pizzorno; Kurenai Tanji; Fernando Arias-Mendoza; Caterina M Quinzii; Michio Hirano
Journal:  Brain       Date:  2014-04-10       Impact factor: 13.501

Review 9.  Thymidine phosphorylase: A potential new target for treating cardiovascular disease.

Authors:  Wei Li; Hong Yue
Journal:  Trends Cardiovasc Med       Date:  2017-10-20       Impact factor: 6.677

10.  Long-Term Restoration of Thymidine Phosphorylase Function and Nucleoside Homeostasis Using Hematopoietic Gene Therapy in a Murine Model of Mitochondrial Neurogastrointestinal Encephalomyopathy.

Authors:  Javier Torres-Torronteras; Raquel Cabrera-Pérez; Ignasi Barba; Carme Costa; Noemí de Luna; Antoni L Andreu; Jordi Barquinero; Michio Hirano; Yolanda Cámara; Ramon Martí
Journal:  Hum Gene Ther       Date:  2016-05-04       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.